Plain-English translation of NCT07187635 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Read our Bladder Cancer research guide →This study doesn't follow the usual testing phases — it may be an observational study or a different type of research.
This study is testing whether a urine tumor DNA (utDNA) test can help doctors make smarter decisions about who needs a second bladder cancer surgery. Many patients undergo this repeat surgery as routine care, but not all of them actually have leftover cancer. The trial wants to see if the urine test can identify which patients truly need the surgery and which ones can safely skip it.
About three-quarters of new bladder cancer cases are caught early, but they have a high risk of coming back. Current guidelines recommend all high-risk patients get a second surgery within 2–6 weeks, even though many don't actually have any remaining cancer. This repeat surgery carries risks, costs, and burdens for patients, so doctors need a better way to figure out who really needs it.
You likely qualify if…
You likely don't qualify if…
You will be randomly assigned to one of two groups. If assigned to the standard group, you will have the second surgery as normally recommended. If assigned to the urine test group, you will provide a urine sample 2–6 weeks after your first surgery; if the test is positive for tumor DNA, you'll have the second surgery, but if it's negative, you'll skip the surgery and continue with surveillance instead. Either way, you'll provide tissue samples for examination and participate in genetic testing.
AI-generated summary from trial data · Aug 19, 2026 · Not medical advice
China